The content of this website is intended for United States audiences only.
A Phase 3 Asian Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in Subjects With Hormonal Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer (MBC) Who Have Failed at Least 2 Prior Chemotherapy Regimens
The goal of this study is to compare the study drug, sacituzumab govitecan-hziy, versus doctors' treatment of choice in participants with HR+/HER2- metastatic breast cancer (MBC) who have failed at least 2 prior chemotherapy regimens.
View More
Age
18 Years +
Sex
ALL
Healthy Volunteers
No
Medical Condition
Metastatic Breast Cancer
Gender
N/A
Date
November 2020 - December 2026
Study Type
INTERVENTIONAL
Study Phase
PHASE3
Product
Sacituzumab Govitecan-hziy, Eribulin Mesylate Injection, Capecitabine Oral Product, Gemcitabine Injection, Vinorelbine injection
Beijing, China,
Beijing, China,
Beijing, China,
Changchun, China,
Changchun, China,
Chengdu, China,
Chengdu, China,
Fuzhou, China,
Guangzhou, China,
Guangzhou, China,
Guangzhou, China,
Hangzhou, China,
Hangzhou, China,
Hefei, China,
Hefei, China,
Jinan, China,
Kunming, China,
Linyi, China,
Nanjing, China,
Nanjing, China,
Shanghai, China,
Tianjin, China,
Ürümqi, China,
Wuhan, China,
Wuhan, China,
Xi'an, China,
Zhengzhou, China,
Busan, South Korea,
Seongnam, South Korea,
Seoul, South Korea,
Seoul, South Korea,
Seoul, South Korea,
Seoul, South Korea,
Seoul, South Korea,
Suwon, South Korea,
Changhua, Taiwan,
Kaohsiung City, Taiwan,
Taichung, Taiwan,
Tainan, Taiwan,
Taipei, Taiwan,
Taipei, Taiwan,
Taipei, Taiwan,
Taoyuan, Taiwan,
Share Trial